Halogenated and metallic scaffolds as novel efflux pump inhibitors: mechanistic insight in overcoming antimicrobial and cross-domain resistance
- 1Department of Biology, Faculty of Education and Arts, Sohar University, Sohar, Oman
- 2Department of Engineering, University of South Florida, Tampa, FL, United States
- 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States
Abstract
Antimicrobial resistance (AMR) is increasing rapidly, necessitating the development of non-traditional therapeutic approaches. Overexpression of bacterial efflux pumps mediates active extrusion of drugs and is a major mechanism underlying multidrug resistance (MDR) in both Gram-negative and Gram-positive pathogens. Inhibition of efflux pumps (EPIs) can restore the activity of conventional antibiotics that have lost efficacy due to resistance. Here, we examine two classes of non-antibiotic adjuvants: halogenated small molecules and metal-based coordination complexes or nanoparticles. Halogen bonding and related chemical modifications can modulate membrane permeability and influence binding kinetics within bacterial transporters. Metal-based antimicrobial compounds utilize specific three-dimensional geometries and iron-mimicry to disrupt microbial transport systems. Notably, although microbial efflux pumps and mammalian multidrug transporters are structurally and mechanistically distinct, they share a functional role in reducing intracellular drug accumulation. This functional convergence provides a rationale for investigating whether selected EPI scaffolds developed in antimicrobial systems may also modulate resistance-associated transport processes in cancer. However, evidence supporting such cross-domain activity remains predominantly preclinical, and functional activity in one biological system should not be interpreted as evidence of therapeutic equivalence or clinical transferability to the other. By integrating structure–activity relationships, transporter mechanisms, microenvironmental pH effects, and translational limitations, this review highlights the potential of halogenated and metal-based scaffolds as experimental EPI platforms while emphasizing the substantial pharmacological, safety, and validation challenges that remain before clinical application.
Related
- Discovery of a Virulent Population of Meloidogyne graminicola Overcoming the Rice Resistance Gene MG1 and Population Genetic Analysis Based on mtCOI Sequences
- Targeting Hippo-MAPK crosstalk in schwannoma: Overcoming resistance with dual inhibition.
- Extrachromosomal DNA: A New Therapeutic Frontier for Overcoming Cancer Drug Resistance
- Spatial and single-cell insights into the prostate cancer microenvironment: overcoming immunotherapy resistance through multidimensional strategies
- Antimicrobial Resistance (AMR) Surveillance: Ten Years On.
BibTeX
@article{almatar2026halogenated,
title = {{Halogenated and metallic scaffolds as novel efflux pump inhibitors: mechanistic insight in overcoming antimicrobial and cross-domain resistance}},
author = {Manaf AlMatar and Raja Lakhal and Kamaleldin H. Kamaleldin and Arig Ibrahim-Hashim},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1923157},
url = {https://doi.org/10.3389/fmicb.2026.1923157},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Halogenated and metallic scaffolds as novel efflux pump inhibitors: mechanistic insight in overcoming antimicrobial and cross-domain resistance
AU - Manaf AlMatar
AU - Raja Lakhal
AU - Kamaleldin H. Kamaleldin
AU - Arig Ibrahim-Hashim
PY - 2026
DA - 2026/10/12
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1923157
UR - https://doi.org/10.3389/fmicb.2026.1923157
AB - Antimicrobial resistance (AMR) is increasing rapidly, necessitating the development of non-traditional therapeutic approaches. Overexpression of bacterial efflux pumps mediates active extrusion of drugs and is a major mechanism underlying multidrug resistance (MDR) in both Gram-negative and Gram-positive pathogens. Inhibition of efflux pumps (EPIs) can restore the activity of conventional antibiotics that have lost efficacy due to resistance. Here, we examine two classes of non-antibiotic adjuvants: halogenated small molecules and metal-based coordination complexes or nanoparticles. Halogen bonding and related chemical modifications can modulate membrane permeability and influence binding kinetics within bacterial transporters. Metal-based antimicrobial compounds utilize specific three-dimensional geometries and iron-mimicry to disrupt microbial transport systems. Notably, although microbial efflux pumps and mammalian multidrug transporters are structurally and mechanistically distinct, they share a functional role in reducing intracellular drug accumulation. This functional convergence provides a rationale for investigating whether selected EPI scaffolds developed in antimicrobial systems may also modulate resistance-associated transport processes in cancer. However, evidence supporting such cross-domain activity remains predominantly preclinical, and functional activity in one biological system should not be interpreted as evidence of therapeutic equivalence or clinical transferability to the other. By integrating structure–activity relationships, transporter mechanisms, microenvironmental pH effects, and translational limitations, this review highlights the potential of halogenated and metal-based scaffolds as experimental EPI platforms while emphasizing the substantial pharmacological, safety, and validation challenges that remain before clinical application.
SN - 1664-302X
ER -